Supercharging A New FDA: Marty Makary on Science, Power & Patients
FDA Commissioner Dr. Marty Makary is transforming drug approvals by reducing requirements from two pivotal trials to one, eliminating animal testing, and introducing rapid review pathways that approve drugs in weeks instead of years. His core insight: unnecessary delays in approval processes aren't
1h 29mKey Takeaway
FDA Commissioner Dr. Marty Makary is transforming drug approvals by reducing requirements from two pivotal trials to one, eliminating animal testing, and introducing rapid review pathways that approve drugs in weeks instead of years. His core insight: unnecessary delays in approval processes aren't just bureaucratic inefficiencies—they cost lives. When patients are dying from diseases we could treat, speed becomes a safety issue, not a risk.
Episode Overview
Dr. Marty Makary, FDA Commissioner, discusses his mission to modernize the FDA and accelerate drug approvals while maintaining safety standards. He addresses the US-China biotech race, explaining how regulatory inefficiencies have put America behind. Makary outlines 42 major reforms implemented in his first year, including reducing pivotal trial requirements, eliminating animal testing, using AI for faster reviews, and creating priority pathways that can approve drugs in 55 days instead of years. He emphasizes that delays in the approval process pose their own safety risks—patients die waiting for treatments that could save them. The conversation covers cell and gene therapy reforms, continuous trial monitoring using Bayesian statistics, post-market surveillance with big data, and the Right to Try program. Makary's approach balances innovation speed with safety, arguing that modernizing outdated processes is essential to compete globally and save American lives.
Key Insights
Regulatory Delays Are a Safety Issue, Not Just Inefficiency
Makary reframes the drug approval timeline debate: when it takes 10-12 years to bring a drug to market, patients with terminal illnesses die waiting for treatments that could save them. Unnecessary delays—like requiring 144 chimpanzees for monoclonal antibody testing or waiting 60 days just to acknowledge an application—aren't protecting safety; they're creating risk by denying access to potentially life-saving treatments.
America Is Losing the Biotech Race to China
Chinese companies have gone from 5% of licensing deals in 2022 to 42% in 2025. China completes Phase 1 trials in 4 weeks; America takes months or years. The solution isn't just protectionism—it's becoming more competitive by streamlining IRB approvals, centralizing hospital contracting, and reducing red tape that drives innovation overseas.
From Two Pivotal Trials to One Saves $100-300 Million and Years
The FDA's new default is one well-designed pivotal trial instead of two. This achieves the same statistical power with proper study design and control groups, cutting hundreds of millions in costs and significantly shortening approval timelines. This enables companies to run twice as many drugs through trials with the same resources.
Eliminating Animal Testing Produces Better, Faster Results
90% of drugs that pass animal studies fail safety and efficacy in humans. The FDA eliminated chimpanzee study requirements for monoclonal antibodies (saving 144 animals and 8 months per drug) and is expanding use of computational modeling and organ-on-a-chip technology, which provide more accurate predictions of human responses than animal studies.
Continuous Trials with Bayesian Statistics Enable Real-Time Approvals
Instead of waiting for committees to meet twice yearly to review data, the FDA now allows Bayesian statistical evaluation to identify safety signals or established efficacy in real time. This enables calling trials early when success is proven, getting effective drugs to patients faster, and using AI tools for continuous monitoring rather than periodic reviews.
Post-Market Surveillance with Big Data Prevents Future Vioxx Disasters
The FDA learned 5 years after Vioxx approval that it may have killed 38,000 people. Modern big data surveillance can identify safety signals in real time, catching problems like the opioid epidemic early. Continuous monitoring can also detect drug-drug interactions and effects in specific subpopulations, enabling faster warnings and interventions.
Customized Manufacturing Requirements for Cell and Gene Therapy
The FDA eliminated rigid manufacturing requirements (like three batch runs costing $100,000 each) for cell and gene therapies. These bespoke therapies developed in university labs don't need the same mass manufacturing standards as pills. The new approach customizes requirements based on the drug, platform, and population being treated.
Notable Quotes
"My number one priority is not to censor Americans. It's to deliver more cures and meaningful treatments faster to the American public and healthier food for children."
"Why does it take 10 to 12 years for a new drug to come to market? We've become so lukewarm and passive accepting that horrible timeline that has just become the status quo. We've got to challenge these deeply held assumptions."
"Having 8 months of 144 chimpanzees go undergoing studies has risks to the general public. You may be holding back a curative medication for 8 months."
"90% of drugs that pass animal studies do not pass safety and efficacy in humans. So what are we doing?"
"We announced just last month that we are going to go from a baseline default requirement of two pivotal trials for a drug to one pivotal trial for a drug. It's just math. You can achieve the same statistical power if you design one good clinical trial properly with a good control group."
Action Items
-
1
Understand the True Cost of Regulatory Delays
When evaluating healthcare policy or innovation, recognize that delays aren't neutral—they cost lives. Every month a life-saving treatment is delayed represents patients who die waiting. Apply this framework to other areas: what's the cost of moving too slowly on important decisions?
-
2
Challenge 'That's How We've Always Done It' in Your Organization
Makary found FDA employees carrying physical files between buildings because lawyers said they couldn't email them—between departments of the same agency. Identify processes in your work that exist only because 'that's how it's always been done' and question whether they still make sense in the modern world.
-
3
Create Incentive Structures That Reward Speed AND Quality
The FDA changed bonuses to reward reviewers for completing work quickly rather than waiting until the deadline. In your work, examine whether your incentive structures inadvertently reward slowness or busy-work rather than outcomes and efficiency.
-
4
Use Data Continuously, Not Just at Checkpoints
Instead of periodic reviews, implement real-time monitoring systems using modern tools. Whether tracking health metrics, business KPIs, or project progress, continuous data streams enable faster course corrections and better decisions than waiting for quarterly or annual reviews.